These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 9462667)

  • 1. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.
    Melegari M; Scaglioni PP; Wands JR
    Hepatology; 1998 Feb; 27(2):628-33. PubMed ID: 9462667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
    Delaney WE; Yang H; Westland CE; Das K; Arnold E; Gibbs CS; Miller MD; Xiong S
    J Virol; 2003 Nov; 77(21):11833-41. PubMed ID: 14557667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.
    Delaney WE; Miller TG; Isom HC
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2017-26. PubMed ID: 10428929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.
    Allen MI; Deslauriers M; Andrews CW; Tipples GA; Walters KA; Tyrrell DL; Brown N; Condreay LD
    Hepatology; 1998 Jun; 27(6):1670-7. PubMed ID: 9620341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.
    Ono-Nita SK; Kato N; Shiratori Y; Masaki T; Lan KH; Carrilho FJ; Omata M
    Hepatology; 1999 Mar; 29(3):939-45. PubMed ID: 10051501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.
    Warner N; Locarnini S; Kuiper M; Bartholomeusz A; Ayres A; Yuen L; Shaw T
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2285-92. PubMed ID: 17438047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.
    Pichoud C; Seignères B; Wang Z; Trépo C; Zoulim F
    Hepatology; 1999 Jan; 29(1):230-7. PubMed ID: 9862871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.
    Yatsuji H; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Iwao E; Fujimoto Y; Ochi H; Abe H; Maekawa T; Tateno C; Yoshizato K; Suzuki F; Kumada H; Chayama K
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3867-74. PubMed ID: 16982790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus.
    Ling R; Harrison TJ
    J Gen Virol; 1999 Mar; 80 ( Pt 3)():601-606. PubMed ID: 10091998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues.
    Ladner SK; Miller TJ; Otto MJ; King RW
    Antivir Chem Chemother; 1998 Jan; 9(1):65-72. PubMed ID: 9875378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
    Tacke F; Gehrke C; Luedde T; Heim A; Manns MP; Trautwein C
    J Virol; 2004 Aug; 78(16):8524-35. PubMed ID: 15280461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.
    Torresi J; Earnest-Silveira L; Civitico G; Walters TE; Lewin SR; Fyfe J; Locarnini SA; Manns M; Trautwein C; Bock TC
    Virology; 2002 Jul; 299(1):88-99. PubMed ID: 12167344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
    Jacquard AC; Brunelle MN; Pichoud C; Durantel D; Carrouée-Durantel S; Trepo C; Zoulim F
    Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
    Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
    EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
    León P; Pozo F; Echevarría JM
    Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):133-7. PubMed ID: 14987532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
    Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
    Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine.
    Tatti KM; Korba BE; Stang HL; Peek S; Gerin JL; Tennant BC; Schinazi RF
    Antiviral Res; 2002 Jul; 55(1):141-50. PubMed ID: 12076758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.